Hepatitis C is a viral infection that causes inflammation and damage to the liver, requiring a liver transplant if not ...
Renowned Tamil filmmaker Suresh Sangaiah passed away in Chennai on Friday, November 15, at the Rajiv Gandhi Hospital, ...
Researchers develop a plug-and-play test that enables real-time monitoring of engineered T-cells, improving the precision and ...
Arbutus Biopharma (ABUS) and Barinthus Biotherapeutics (BRNS) announced new preliminary data from the Phase 2a IM-PROVE II clinical trial of ...
On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study ...
Precision BioSciences (DTIL) will present preclinical data supporting the advancement of PBGENE-HBV into clinical development. The company will ...
A novel test enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient. This simple and innovative test provides ...
HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional ...
GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.
50% of patients (3/6) with baseline HBsAg <1000 IU/mL achieved a functional cure (defined as sustained HBsAg loss and HBV DNA ...
No new safety findings were observed. The most common treatment-emergent adverse events (>10 percent) occurring more ...
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback